Event overview and why Johnson & Johnson is on investors’ radar

Johnson & Johnson (JNJ) stock is drawing attention after fresh performance metrics highlighted its scale, with revenue of US$96.4b and net income of US$21.0b across its Innovative Medicine and MedTech segments.

The stock’s recent momentum has been mixed, with a 1-month share price return of 3.01% and year to date share price return of 13.02%, while the 3-month share price return declined 4.85%. However, longer term total shareholder returns of 57.49% over 1 year and 64.77% over 3 years point to a stronger multi year picture.

If Johnson & Johnson’s move has you thinking about healthcare opportunities tied to new technology, it may be worth scanning 34 healthcare AI stocks.

With Johnson & Johnson trading at US$234.34 alongside analyst targets of US$252.96 and an estimated intrinsic value gap of 37%, investors now face a key question: is there genuine upside left, or is the stock already pricing in future growth?

Most Popular Narrative: 35% Overvalued

According to the most followed narrative for Johnson & Johnson, the fair value estimate of $173.55 sits well below the last close of $234.34, which puts the current share price at a material premium to that assessment.

Extending my 22x PE estimate to 2029, with a net income estimate of $24B, I get a future value of $528B, around $230 per share for JNJ. Discounting back to today using Simply Wall St’s 5.8% rate, I get a new present value of $174 per share, which is $5 higher than my prior valuation estimate.

Curious what is behind that lower fair value even with solid earnings forecasts and high margins in the model? The answer rests on a tight mix of revenue growth, profitability and the future earnings multiple that this narrative assigns to Johnson & Johnson, and how that compares to today’s price.

Result: Fair Value of $173.55 (OVERVALUED)

However, this depends on key risks, including unresolved lawsuits and patent expirations, which could pressure earnings and challenge the optimistic valuation narrative.

Another view on Johnson & Johnson’s value

The user narrative pins fair value at $173.55, implying the stock is 35% overvalued, but Simply Wall St’s DCF model tells a very different story. On that view, JNJ at $234.34 sits around 37% below an estimated future cash flow value of $374.05. Which story do you lean toward?

Next Steps

The split between the user narrative and the DCF view shows how differently the same stock can look, so take a moment to review the numbers, weigh the legal and growth factors, and check the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If Johnson & Johnson has sharpened your focus, do not stop here. Broaden your watchlist with stocks that match the kind of portfolio you want to build.

• Target potential value opportunities by scanning 48 high quality undervalued stocks, which combine strong fundamentals with appealing price tags.
• Prioritize resilience by reviewing 69 resilient stocks with low risk scores, which may offer steadier profiles when markets swing.
• Hunt for future standouts before the crowd pays attention by checking screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.